Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered on the stock's notable price movements in early October, with many users pointing to rising support and increasing momentum as signs of a potential breakout. There’s a palpable excitement around the company’s AI-driven drug discovery platform, with some expressing optimism about its long-term potential to revolutionize the biotech sector. The chatter often highlights specific price targets and resistance levels, reflecting a keen interest in near-term technical trends.
However, not all sentiment is uniformly positive, as some voices on X raise concerns about broader challenges in the biotech industry and recent insider activity that has sparked debate about internal confidence. Despite these reservations, the anticipation around upcoming pipeline updates and strategic developments continues to fuel engagement. The conversation remains dynamic, with a mix of speculative enthusiasm and cautious analysis driving the narrative.
Note: This discussion summary was generated from an AI condensation of post data.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 6 sales selling 918,175 shares for an estimated $4,694,964.
- NAJAT KHAN (Chief R&D Commercial Officer) sold 36,599 shares for an estimated $202,172
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 166 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 146 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 4,864,474 shares (+20.7%) to their portfolio in Q2 2025, for an estimated $24,614,238
- VANGUARD GROUP INC added 3,783,201 shares (+11.7%) to their portfolio in Q2 2025, for an estimated $19,142,997
- STATE STREET CORP removed 1,905,719 shares (-14.6%) from their portfolio in Q2 2025, for an estimated $9,642,938
- ARK INVESTMENT MANAGEMENT LLC removed 1,826,871 shares (-5.2%) from their portfolio in Q2 2025, for an estimated $9,243,967
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,793,008 shares (-28.0%) from their portfolio in Q2 2025, for an estimated $9,072,620
- DIMENSIONAL FUND ADVISORS LP removed 1,682,722 shares (-98.0%) from their portfolio in Q2 2025, for an estimated $8,514,573
- LAURION CAPITAL MANAGEMENT LP removed 1,547,407 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,829,879
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 2 analysts offer price targets for $RXRX in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Gil Blum from Needham set a target price of $8.0 on 09/11/2025
- Vikram Purohit from Morgan Stanley set a target price of $5.0 on 07/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
